Biocon executive chairperson Kiran Mazumdar-Shaw tests COVID-19 positive

Biocon's Kiran Mazumdar Shaw tweeted stating, "I have added to the Covid count by testing positive..." 

<p>Executive chairperson of Bengaluru-headquartered Biocon Ltd Kiran Mazumdar-Shaw tested positive for coronavirus on August 17.&nbsp;</p>

Executive chairperson of Bengaluru-headquartered Biocon Ltd Kiran Mazumdar-Shaw tested positive for coronavirus on August 17. 

<p>She took to Twitter to announce the news stating, "I have added to the covid count by testing positive. Mild symptoms and I hope it stays that way."</p>

She took to Twitter to announce the news stating, "I have added to the covid count by testing positive. Mild symptoms and I hope it stays that way."

<p><br />The 67-year-old biotechnology industry veteran received hundreds of get-well-soon messages after she posted the tweet.<br />&nbsp;</p>

The 67-year-old biotechnology industry veteran received hundreds of get-well-soon messages after she posted the tweet.

<p><br />In the state, chief minister BS Yediyurappa, Leader of Opposition Siddaramaiah and state Health Minister B Sriramulu have recovered from COVID-19.</p>

In the state, chief minister BS Yediyurappa, Leader of Opposition Siddaramaiah and state Health Minister B Sriramulu have recovered from COVID-19.

<p><br />According to reports, Bengaluru Urban district has the biggest number of coronavirus cases in Karnataka with over 91,000 cases.</p>

According to reports, Bengaluru Urban district has the biggest number of coronavirus cases in Karnataka with over 91,000 cases.

<p><br />&nbsp;</p><p>Biocon is one of the companies looking to develop a vaccine to fight COVID-19. In July, regulator the Drug Controller General of India (DCGI) allowed it to market a repurposed injection, Itolizumab, which was originally launched in 2013 for treating chronic plaque psoriasis.</p>

Biocon is one of the companies looking to develop a vaccine to fight COVID-19. In July, regulator the Drug Controller General of India (DCGI) allowed it to market a repurposed injection, Itolizumab, which was originally launched in 2013 for treating chronic plaque psoriasis.